Metro-Minnesota Community Clinical Oncology Program (MM-CCOP)

明尼苏达都会区社区临床肿瘤学计划 (MM-CCOP)

• 批准号: 9116801
• 负责人: Daniel M Anderson
• 金额: $ 258万
• 依托单位: HEALTHPARTNERS INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2019-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9116801
• 关键词: Address; Affect; American Cancer Society; American College of Radiology Imaging Network; American College of Surgeons Oncology Group; Area; Award; Awareness; Cancer Center; Cancer Control; Cancer Information Service; Cancer Patient; Cancer Research Project; Cancer and Leukemia Group B; Caring; Chemoprevention; Clinical Oncology; Clinical Research; Clinical Trials; Clinical Trials Support Unit; Clinics and Hospitals; Collaborations; Communication; Communities; Community Clinical Oncology Program; Community Hospitals; Comprehensive Cancer Center of Wake Forest University; Controlled Study; Data; Data Collection; Decision Making; Development; Doctor of Medicine; Eastern Cooperative Oncology Group; Enrollment; Environment; Evaluation; Funding; Goals; Grant; Growth; Gynecologic Oncology; Gynecologic Oncology Group; Health; Health Care Reform; Health Planning; Health Planning Councils; Health Professional; Hematology; Hospital Administration; Hospitals; Improve Access; Institutes; Institution; Institutional Review Boards; Knowledge; Link; Malignant Neoplasms; Marketing; Medical; Minnesota; Minority Participation; Modeling; Molecular Target; National Cancer Institute; National Surgical Adjuvant Breast and Bowel Project; Natural History; North Central Cancer Treatment Group; Nursing Societies; Oncologic Nursing; Oncologist; Oncology Nurse; Operations Research; Outcome; Pamphlets; Participant; Patient Recruitments; Patients; Patterns of Care; Physicians; Primary Care Physician; Protocols documentation; Quality of life; Radiation Oncology; Radiation Therapy Oncology Group; Recording of previous events; Reporting; Research; Research Infrastructure; Research Personnel; Resources; Screening for cancer; Specialist; Surgical Oncology; System; Thoracic Surgical Procedures; Time; Toxic effect; Treatment-related toxicity; Underrepresented Populations; Underserved Population; Universities; Wisconsin; anticancer research; base; cancer care; cancer clinical trial; cancer prevention; cancer therapy; care delivery; data management; follow-up; improved; meetings; member; metropolitan; novel therapeutics; oncology program; organizational structure; programs; protocol development; racial and ethnic; research and development; research study; service utilization; success; symptom management; symptom treatment; targeted agent; underserved minority; web site

DESCRIPTION (provided by applicant): The Metro-Minnesota Community Clinical Oncology (MMCCOP) program has a long-standing history which clearly demonstrates the success of the consortium, as demonstrated by both the ongoing commitment of the original consortium members and the growth of the consortium from 1979 through 2014. The MMCCOP consortium represents an established community program base which began in 1979 through its NCI-funded Community Hospital Cancer Program (CHCP) Award. This same consortium applied for and received the initial Community Clinical Oncology Program (CCOP) grant from the NCI in 1983, and has received subsequent CCOP grants since that time. In 2010, hospital, clinics and oncologists in the MN CGOP program joined the MMCOP resulting in a metrowide community cancer research program. Currently, the MMCCOP consortium represents twenty-one hospital and clinics throughout the metropolitan and greater Minnesota area, with a common approach and established mechanisms for identifying, enrolling and following participants on NC-sponsored treatment, cancer prevention, cancer control and symptom management protocols. The health market in the MMCCCP community remains extremely competitive and is in constant change as a result of mergers and Minnesota's healthcare reform initiatives. Despite this changing environment, the MMCCOP hospitals and associated staff continue to collaborate and support the added time and expense involved in clinical research trials. Their level of support has increased during a time when many other projects within the hospitals are being reduced or eliminated. This program incorporates a substantial segment of the oncology community, and has provided a basis for communications between the practicing oncologists, their hospital administrations, and other health professionals in this consortium for the past thiry years. Combined, the consortium members see an average of over 15,000 new analytic cancer patients per year. Currently, there are 146 Investigators, representing medical, hematology, radiation and surgical oncology including thoracic surgery and gynecologic oncology. The history of MMCCOP Research Base Affiliations and proactive approach to expanding access to NCI sponsored studies supports the ability to achieve and maintain the NCI goals for this NCORP initiative. MMCCOP intends to sustain a region wide community consortium which provides the community with the most recent advances in cancer prevention, treatment, symptom management and care delivery. This will be accomplished through continued affiliations with ALL1ANCE,CTSU, ECOG-ACRIN, NRG, MD Anderson, URCC and CCCWFU, the expansion of the current MMCCOP data management and communication system to increase the number and level of participation of the investigators in accrual, program operations and research base activities, implementation of new strategies to improve access and participation of underrepresented and underserved groups, and increase the professional and lay community awareness of the benefits of cancer research and collaboration with the MMCCOP to achieve the goals of the NCORP. A new focus will be to further develop and utilize expertise and data within the consortium and community to provide data and conduct cancer care delivery research. All member institutions are members of the Institutional Review Board for the Community Oncology Programs, administered by Park Nicollet Institute, which provides an efficient and timely review of studies. Over the past 5 years an average of 250 patients and 400 patients were accrued to NCI-approved treatment studies and cancer control studies respectively. Additionally, there are 1666 participants in active follow-up or surveillanc. MMCCCOP has demonstrated the ability to enter an increasing number of patients on protocol each year and proposes to accrue a total of 260 credits to Treatment studies and 400 to Cancer Control and Cancer Care Delivery research studies in the first year of this award with the goal of increasing cancer care delivery research enrollments over the next 5 year. This is a well tuned research consortium with the ability to be fully operational on day one of the award.

描述（由申请人提供）：Metro-Minnesota社区临床肿瘤学（MMCCOP）计划具有悠久的历史，清楚地证明了该财团的成功，正如原始财团成员的持续承诺所证明的，并从1979年到2014年的联盟成长以及MMCCOP Consortium的NOBLECT COFTIUMS COMPLIUM COMPORTIUM SPORTION COMPARIEN COMPARIER SPORATION。同一财团申请并获得了1983年NCI的最初社区临床肿瘤学计划（CCOP）赠款，并从那时起就获得了随后的CCOP赠款。 2010年，MN CGOP计划中的医院，诊所和肿瘤学家加入了MMCOP，从而制定了Metrowide社区癌症研究计划。目前，MMCCOP联盟代表整个大都会和大明尼苏达州地区的21家医院和诊所，采用了一种常见的方法和确定，入学和关注参与者进行NC赞助的治疗，预防癌症，癌症控制和症状管理方案的既定机制。 MMCCCP社区的健康市场仍然非常竞争，并且由于合并和明尼苏达州的医疗改革计划而不断变化。尽管环境不断变化，但MMCCOP医院和相关人员仍继续协作并支持临床研究试验中涉及的增加时间和费用。在医院内许多其他项目被减少或消除的时期，他们的支持水平也有所提高。该计划结合了肿瘤学社区的大量部分，并为过去三年的肿瘤学家，医院管理部门和其他卫生专业人员之间的沟通提供了依据。联盟成员总共看到每年平均有15,000多名新的分析癌患者。目前，有146名研究人员，代表医学，血液学，放射线和外科肿瘤学，包括胸腔手术和妇科肿瘤学。 MMCCOP研究基础隶属关系的历史和积极的方法来扩大对NCI赞助的研究的访问，这支持了实现和维护该NCORP倡议的NCI目标的能力。 MMCCOP打算维持一个地区广泛的社区财团，为社区提供预防癌症，治疗，症状管理和护理的最新进展。这将通过与All1ance，CTSU，Ecog-Acrin，NRG，MD Anderson，Anderson，URCC和CCCWFU的持续联系来实现，这是当前的MMCCOP数据管理和通信系统的扩展，以增加调查人员参与的参与数量和水平意识到癌症研究的好处和与MMCCOP合作以实现NCORP的目标。一个新的重点是进一步发展和利用财团和社区内的专业知识和数据来提供数据并进行癌症护理提供研究。所有会员机构均为Park Nicollet Institute管理的社区肿瘤学计划机构审查委员会的成员，该计划提供了有效且及时的研究审查。在过去的5年中，平均有250名患者和400名患者分别接受NCI批准的治疗研究和癌症对照研究。此外，还有1666名参与者进行了积极的随访或监视。 MMCCCOP表明，每年都有越来越多的患者在治疗研究中加入260个学分，并在该奖项的第一年中获得了400个学分，并提出400个学分，并在接下来的5年内提高了癌症护理护理提供研究的招生。这是一个精心调整的研究联盟，能够在该奖项的第一天全面运作。